<p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics Incorporated（NYSE:DGX - 免费报告）的持股，根据该公司最近向 SEC 提交的文件，持股增长了 75.4%。该基金在本季度购买了额外的 1,648 股，持有这家医疗研究公司的 3,834 股股票。Cypress Capital Group 在最新报告期结束时持有的 Quest Diagnostics 股票价值为$525,000。</p>
<p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
<ul>
<li>Myriad Genetics 通过遗传癌症检测看到股价飙升</li>
</ul>
<p>其他一些大型投资者最近也增加或减少了对该公司的持股。路易斯安那州雇员退休系统在第四季度收购了 Quest Diagnostics 股票的新股份，价值约为$938,000。Lindbrook Capital LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增长了 120.7%。Lindbrook Capital LLC 现在拥有 415 股这家医疗研究公司股票，价值$57,000，比上一季度多购买了 227 股。Signaturefd LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增长了 43.7%。Signaturefd LLC 现在拥有 1,374 股这家医疗研究公司股票，价值$189,000，期间又购买了 418 股。CWM LLC 在第四季度增加了对 Quest Diagnostics 的持股，持股增长了 1.3%。CWM LLC 现在拥有 18,200 股这家医疗研究公司股票，价值$2,509,000，比上一季度多购买了 232 股。最后，GAMMA Investing LLC 在第四季度收购了 Quest Diagnostics 的新股份，价值$67,000。该股票的 88.06% 由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>DGX 已成为多家研究分析师报告的主题。StockNews.com 在 7 月 23 日星期二的研究报告中，将 Quest Diagnostics 的股票评级从 “持有” 调升至 “买入”。Piper Sandler 将 Quest Diagnostics 的价格目标从$145.00 上调至$150.00，并给予股票 “中性” 评级。Truist Financial 将 Quest Diagnostics 的目标价从$150.00 上调至$158.00，并在 7 月 15 日星期一的研究报告中给予该公司 “持有” 评级。Robert W. Baird 将 Quest Diagnostics 的目标价从$153.00 上调至$154.00，并在 7 月 24 日星期三的研究报告中给予股票 “中性” 评级。最后，摩根大通将 Quest Diagnostics 的目标价从$152.00 上调至$155.00，并在 5 月 30 日星期四的研究报告中给予该公司 “中性” 评级。八位投资分析师对该股票给予持有评级，五位对该公司股票给予买入评级。根据 MarketBeat，该股票目前的共识评级为 “持有”，共识目标价为$150.58。</p>
<p><strong>阅读我们对 Quest Diagnostics 的最新分析</strong></p>
<h2>Quest Diagnostics 股票表现</h2>
<p>周一交易时间，DGX 股票上涨$0.69，达到$154.25。该股票的交易量为 79,501 股，相比平均交易量 967,391 股。该股票的 50 天简单移动平均线为$144.29，200 天简单移动平均线为$137.03。Quest Diagnostics Incorporated 的 52 周最低价为$119.59，52 周最高价为$154.71。该股票的市值为 171.4 亿美元，市盈率为 20.67，市盈增长比为 2.69，β系数为 0.89。该公司的资产负债比为 0.57，流动比率为 1.00，速动比率为 0.91。</p>
<p>Quest Diagnostics（NYSE:DGX - 获取免费报告）最近公布了其季度收益报告，报告日期为 7 月 23 日星期二。这家医疗研究公司在该季度报告中每股盈利为$2.35，超过了分析师预期的$2.31。该季度业务收入为 24 亿美元，超过了分析师对 23.9 亿美元的预期。Quest Diagnostics 的净资产回报率为 15.35%，净利润率为 8.99%。该季度公司的收入同比增长了 2.5%。在去年同期的同一季度，该公司每股盈利为$2.30。分析师预测，Quest Diagnostics Incorporated 本财年的每股盈利将达到 8.89 美元。</p>
<h2>Quest Diagnostics 股息宣布</h2>
<p>该公司最近宣布了季度股息，将于 10 月 21 日星期一支付。截至 10 月 4 日星期五持股的股东将获得 0.75 美元的股息。这代表每年 3.00 美元的股息和 1.94% 的股息率。除权日为 10 月 4 日星期五。Quest Diagnostics 的派息比率为 40.38%。</p>
<h2>Quest Diagnostics 内部交易</h2>
<p>在其他 Quest Diagnostics 的消息中，高级副总裁 Mark E. Delaney 于 7 月 24 日星期三进行了一笔交易，卖出了 420 股 Quest Diagnostics 股票。这些股票的平均价格为$143.08，总价值为$60,093.60。交易完成后，这位高级副总裁在公司中持有 5,019 股股票，价值约为$718,118.52。该交易已在证券交易委员会的备案中披露，可通过 SEC 网站查看。公司股份的 0.79% 由公司内部持有。</p>
<h2>Quest Diagnostics 简介（免费报告）</h2>
<p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，包括常规、非常规和高级临床测试、解剖病理测试和其他诊断信息服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比药明康德更喜欢的股票</li>
<li>如何计算投资回报率（ROI）</li>
<li>艾礼莉的通往下一个万亿市值之路</li>
<li>内部人士出售解读：能指导你的投资选择吗？</li>
<li>Mobileye Global：CEO 对未来实力押注 1000 万美元</li>
<li>交通运输股投资</li>
<li>3 家公司在降息之前增加股息支付</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速、最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 拥有的 3 只股息股票（来自 DTI）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3"/></p>
<h2>现在是否值得投资 1000 美元购买药明康德？</h2>
<p>在考虑药明康德之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票，而药明康德不在名单上。</p>
<p>尽管药明康德目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奎斯特诊疗

<p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics（纽约证券交易所：DGX）的持股，增幅为 75.4%，增持了 1,648 股，使其持股总数达到 3,834 股。其他几家机构也调整了他们在该公司的持股。Quest Diagnostics 的股票目前在分析师中有共识的 “持有” 评级，目标股价为 66.58 美元。该公司第二季度每股盈利为 1.35 美元，超过了预期，并宣布每股 0.75 美元的季度股息，将于 10 月 21 日支付</p>

<p>Cypress Capital Group lifted its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 75.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,834 shares of the medical research company's stock after purchasing an additional 1,648 shares during the quarter. Cypress Capital Group's holdings in Quest Diagnostics were worth $525,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics Incorporated（NYSE:DGX - 免费报告）的持股，根据该公司最近向 SEC 提交的文件，持股增长了 75.4%。该基金在本季度购买了额外的 1,648 股，持有这家医疗研究公司的 3,834 股股票。Cypress Capital Group 在最新报告期结束时持有的 Quest Diagnostics 股票价值为$525,000。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
<ul>
<li>Myriad Genetics 通过遗传癌症检测看到股价飙升</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at approximately $938,000. Lindbrook Capital LLC lifted its holdings in shares of Quest Diagnostics by 120.7% during the 4th quarter. Lindbrook Capital LLC now owns 415 shares of the medical research company's stock valued at $57,000 after purchasing an additional 227 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Quest Diagnostics by 43.7% in the fourth quarter. Signaturefd LLC now owns 1,374 shares of the medical research company's stock valued at $189,000 after buying an additional 418 shares during the period. CWM LLC increased its position in shares of Quest Diagnostics by 1.3% during the fourth quarter. CWM LLC now owns 18,200 shares of the medical research company's stock worth $2,509,000 after acquiring an additional 232 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth $67,000. 88.06% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也增加或减少了对该公司的持股。路易斯安那州雇员退休系统在第四季度收购了 Quest Diagnostics 股票的新股份，价值约为$938,000。Lindbrook Capital LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增长了 120.7%。Lindbrook Capital LLC 现在拥有 415 股这家医疗研究公司股票，价值$57,000，比上一季度多购买了 227 股。Signaturefd LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增长了 43.7%。Signaturefd LLC 现在拥有 1,374 股这家医疗研究公司股票，价值$189,000，期间又购买了 418 股。CWM LLC 在第四季度增加了对 Quest Diagnostics 的持股，持股增长了 1.3%。CWM LLC 现在拥有 18,200 股这家医疗研究公司股票，价值$2,509,000，比上一季度多购买了 232 股。最后，GAMMA Investing LLC 在第四季度收购了 Quest Diagnostics 的新股份，价值$67,000。该股票的 88.06% 由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>DGX has been the subject of a number of research analyst reports. StockNews.com raised shares of Quest Diagnostics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday, July 23rd. Piper Sandler increased their price objective on Quest Diagnostics from $145.00 to $150.00 and gave the stock a &#34;neutral&#34; rating in a report on Monday, July 29th. Truist Financial boosted their target price on Quest Diagnostics from $150.00 to $158.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, July 15th. Robert W. Baird upped their price target on Quest Diagnostics from $153.00 to $154.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, July 24th. Finally, JPMorgan Chase &amp; Co. lifted their price objective on shares of Quest Diagnostics from $152.00 to $155.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, May 30th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $150.58.</p>
<ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><p>DGX 已成为多家研究分析师报告的主题。StockNews.com 在 7 月 23 日星期二的研究报告中，将 Quest Diagnostics 的股票评级从 “持有” 调升至 “买入”。Piper Sandler 将 Quest Diagnostics 的价格目标从$145.00 上调至$150.00，并给予股票 “中性” 评级。Truist Financial 将 Quest Diagnostics 的目标价从$150.00 上调至$158.00，并在 7 月 15 日星期一的研究报告中给予该公司 “持有” 评级。Robert W. Baird 将 Quest Diagnostics 的目标价从$153.00 上调至$154.00，并在 7 月 24 日星期三的研究报告中给予股票 “中性” 评级。最后，摩根大通将 Quest Diagnostics 的目标价从$152.00 上调至$155.00，并在 5 月 30 日星期四的研究报告中给予该公司 “中性” 评级。八位投资分析师对该股票给予持有评级，五位对该公司股票给予买入评级。根据 MarketBeat，该股票目前的共识评级为 “持有”，共识目标价为$150.58。</p>
</div><p><strong>Read Our Latest Analysis on Quest Diagnostics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Quest Diagnostics 的最新分析</strong></p>
</div><h2>Quest Diagnostics Stock Performance</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股票表现</h2>
</div><p>DGX stock traded up $0.69 during trading hours on Monday, reaching $154.25. The stock had a trading volume of 79,501 shares, compared to its average volume of 967,391. The stock has a 50-day simple moving average of $144.29 and a 200 day simple moving average of $137.03. Quest Diagnostics Incorporated has a fifty-two week low of $119.59 and a fifty-two week high of $154.71. The stock has a market capitalization of $17.14 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91.</p>
<ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><p>周一交易时间，DGX 股票上涨$0.69，达到$154.25。该股票的交易量为 79,501 股，相比平均交易量 967,391 股。该股票的 50 天简单移动平均线为$144.29，200 天简单移动平均线为$137.03。Quest Diagnostics Incorporated 的 52 周最低价为$119.59，52 周最高价为$154.71。该股票的市值为 171.4 亿美元，市盈率为 20.67，市盈增长比为 2.69，β系数为 0.89。该公司的资产负债比为 0.57，流动比率为 1.00，速动比率为 0.91。</p>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.31 by $0.04. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.39 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.30 EPS. Analysts predict that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Quest Diagnostics（NYSE:DGX - 获取免费报告）最近公布了其季度收益报告，报告日期为 7 月 23 日星期二。这家医疗研究公司在该季度报告中每股盈利为$2.35，超过了分析师预期的$2.31。该季度业务收入为 24 亿美元，超过了分析师对 23.9 亿美元的预期。Quest Diagnostics 的净资产回报率为 15.35%，净利润率为 8.99%。该季度公司的收入同比增长了 2.5%。在去年同期的同一季度，该公司每股盈利为$2.30。分析师预测，Quest Diagnostics Incorporated 本财年的每股盈利将达到 8.89 美元。</p>
</div><h2>Quest Diagnostics Dividend Announcement</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股息宣布</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.94%. The ex-dividend date is Friday, October 4th. Quest Diagnostics's payout ratio is 40.38%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 10 月 21 日星期一支付。截至 10 月 4 日星期五持股的股东将获得 0.75 美元的股息。这代表每年 3.00 美元的股息和 1.94% 的股息率。除权日为 10 月 4 日星期五。Quest Diagnostics 的派息比率为 40.38%。</p>
</div><h2>Insider Transactions at Quest Diagnostics</h2>
<div class="lb-trans"><h2>Quest Diagnostics 内部交易</h2>
</div><p>In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the completion of the sale, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.79% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Quest Diagnostics 的消息中，高级副总裁 Mark E. Delaney 于 7 月 24 日星期三进行了一笔交易，卖出了 420 股 Quest Diagnostics 股票。这些股票的平均价格为$143.08，总价值为$60,093.60。交易完成后，这位高级副总裁在公司中持有 5,019 股股票，价值约为$718,118.52。该交易已在证券交易委员会的备案中披露，可通过 SEC 网站查看。公司股份的 0.79% 由公司内部持有。</p>
</div><h2>Quest Diagnostics Profile (Free Report)</h2>
<div class="lb-trans"><h2>Quest Diagnostics 简介（免费报告）</h2>
</div><p>Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，包括常规、非常规和高级临床测试、解剖病理测试和其他诊断信息服务。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Eli Lilly’s Path to the Next Trillion Market Capitalization</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Mobileye Global: CEO Makes $10 Million Bet on Future Strength</li>
<li>Transportation Stocks Investing</li>
<li>3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比药明康德更喜欢的股票</li>
<li>如何计算投资回报率（ROI）</li>
<li>艾礼莉的通往下一个万亿市值之路</li>
<li>内部人士出售解读：能指导你的投资选择吗？</li>
<li>Mobileye Global：CEO 对未来实力押注 1000 万美元</li>
<li>交通运输股投资</li>
<li>3 家公司在降息之前增加股息支付</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速、最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ 3 dividend stocks to own (From DTI)(Ad)</p>
<div class="lb-trans"><p>→ 拥有的 3 只股息股票（来自 DTI）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8977&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Quest Diagnostics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买药明康德？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票，而药明康德不在名单上。</p>
</div><p>While Quest Diagnostics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管药明康德目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

赛普拉斯资本集团收购了奎斯特诊疗公司（NYSE:DGX）的 1,648 股股票